CR20180583A - Anticuerpos antifactor de la coagulación xi - Google Patents

Anticuerpos antifactor de la coagulación xi

Info

Publication number
CR20180583A
CR20180583A CR20180583A CR20180583A CR20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A CR 20180583 A CR20180583 A CR 20180583A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antifactor
coagulation
fxi
coagulation factor
Prior art date
Application number
CR20180583A
Other languages
English (en)
Inventor
Elizabeth Oldham
Mohammad Tabrizifard
Kenneth P Ellsworth
Dietmar Seiffert
Zhu Chen
James Milligan
Bianka Prinz
Vaishnavi Ganti
Original Assignee
Merck Sharp & Dohme
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Adimab Llc filed Critical Merck Sharp & Dohme
Publication of CR20180583A publication Critical patent/CR20180583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

Se describen anticuerpos que se unen al dominio apple 3 del factor de la coagulación humano XI e inhiben la activación del FXI por el factor de la coagulación XIIa, así como la activación del FXI por el FXa.
CR20180583A 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulación xi CR20180583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
CR20180583A true CR20180583A (es) 2019-07-02

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180583A CR20180583A (es) 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulación xi

Country Status (28)

Country Link
US (6) US10676536B2 (es)
EP (1) EP3469002A1 (es)
JP (2) JP7022081B2 (es)
KR (2) KR102218714B1 (es)
CN (2) CN109476758B (es)
AR (1) AR108717A1 (es)
AU (3) AU2017286432B2 (es)
BR (1) BR112018075858A2 (es)
CA (2) CA3172367A1 (es)
CL (1) CL2018003565A1 (es)
CO (1) CO2018013434A2 (es)
CR (1) CR20180583A (es)
DO (1) DOP2018000284A (es)
EA (1) EA201892716A1 (es)
EC (1) ECSP18091593A (es)
GE (1) GEP20227382B (es)
IL (1) IL263272A (es)
JO (1) JOP20180121A1 (es)
MA (1) MA45234A (es)
MX (2) MX2018015757A (es)
MY (1) MY201852A (es)
NI (1) NI201800134A (es)
PE (1) PE20190416A1 (es)
PH (1) PH12018502586A1 (es)
SG (2) SG10202103120UA (es)
TN (1) TN2018000417A1 (es)
TW (2) TWI752964B (es)
WO (1) WO2017218371A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP7022081B2 (ja) * 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
CA3048156A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
CN114269790B (zh) * 2020-07-02 2023-11-24 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
KR20230035079A (ko) * 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질
CN117480182A (zh) * 2021-02-09 2024-01-30 艾瑞克斯疗法有限公司 抗s100a4人源化抗体、用途和方法
CN116199782A (zh) * 2021-11-30 2023-06-02 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
CA2401342C (en) 2000-03-03 2010-08-03 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
SI1648509T1 (sl) 2003-07-15 2012-12-31 Amgen Inc. Humana protitelesa, ki nevtralizirajo anti-ngf, kot selektivni inhibitorji poti nfg
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
DK1960434T3 (da) 2005-12-08 2012-10-15 Medarex Inc Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
NZ594466A (en) 2005-12-08 2012-08-31 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2497783A3 (en) 2007-09-26 2013-04-17 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
LT3002298T (lt) 2007-11-21 2019-12-10 Univ Oregon Health & Science Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
LT2350304T (lt) 2008-10-31 2017-02-10 Janssen Biotech, Inc. Toll tipo receptoriaus 3 antagonistai
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
CA2889453C (en) 2009-03-20 2018-11-06 Amgen Inc. Carrier immunoglobulins and uses thereof
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CN102459342B (zh) 2009-04-27 2015-01-07 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗il-3ra抗体
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
JP2013519164A (ja) * 2010-02-03 2013-05-23 トリロジー アイピー ホールディングス，インコーポレイテッド モバイル通信プラン提供
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
US20120156130A1 (en) 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment
SG10201509499RA (en) 2010-11-19 2015-12-30 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
PT3424953T (pt) 2011-06-06 2020-11-03 Novo Nordisk As Anticorpos terapêuticos
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PT2650310T (pt) 2012-04-13 2016-09-01 Rottapharm Biotech Srl Anticorpo anti-adamts-5, derivados e utilizações dos mesmos
AU2013258043B2 (en) 2012-05-10 2017-11-30 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor XI and/or its activated form factor XIa and uses thereof
CA2872018A1 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics, Inc. Antigen binding proteins that bind egfr
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3052523B1 (en) 2013-10-01 2021-03-10 Medimmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
JPWO2015141826A1 (ja) 2014-03-20 2017-04-13 国立感染症研究所長 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体
JP6166000B1 (ja) 2014-06-03 2017-07-19 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症を治療および予防するための組成物および方法
EP4066859A1 (en) 2014-08-08 2022-10-05 Alector LLC Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP4435105A2 (en) 2015-09-29 2024-09-25 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2017127468A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
JP7022081B2 (ja) * 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
JP2019537451A (ja) 2016-09-20 2019-12-26 バイエル ファーマ アクチエンゲゼルシャフト 第ｘｉ因子に対する新規抗体およびその用途

Also Published As

Publication number Publication date
US20200317811A1 (en) 2020-10-08
JP7277500B2 (ja) 2023-05-19
MY201852A (en) 2024-03-20
ECSP18091593A (es) 2019-01-31
CA3172367A1 (en) 2017-12-21
TW201802120A (zh) 2018-01-16
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
IL263272A (en) 2018-12-31
CL2018003565A1 (es) 2019-03-22
US20200255542A1 (en) 2020-08-13
TW202214702A (zh) 2022-04-16
TWI752964B (zh) 2022-01-21
SG11201810763TA (en) 2018-12-28
CN116425879A (zh) 2023-07-14
BR112018075858A2 (pt) 2019-04-02
US11661460B2 (en) 2023-05-30
KR102218714B1 (ko) 2021-02-24
AU2020210233A1 (en) 2020-08-20
SG10202103120UA (en) 2021-05-28
TWI802193B (zh) 2023-05-11
EP3469002A1 (en) 2019-04-17
EA201892716A1 (ru) 2019-05-31
GEP20227382B (en) 2022-05-25
DOP2018000284A (es) 2019-01-31
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
JP2019521978A (ja) 2019-08-08
JP2021101720A (ja) 2021-07-15
JP7022081B2 (ja) 2022-02-17
TN2018000417A1 (en) 2020-06-15
AU2020210233B2 (en) 2024-03-07
KR20210021124A (ko) 2021-02-24
AU2017286432A1 (en) 2018-12-06
US11485794B2 (en) 2022-11-01
PE20190416A1 (es) 2019-03-19
CN109476758A (zh) 2019-03-15
PH12018502586A1 (en) 2019-10-07
US20200270364A1 (en) 2020-08-27
AU2017286432B2 (en) 2020-09-24
KR102379580B1 (ko) 2022-03-29
US20200308302A1 (en) 2020-10-01
MX2018015757A (es) 2019-05-30
US20170355780A1 (en) 2017-12-14
MA45234A (fr) 2019-04-17
WO2017218371A1 (en) 2017-12-21
CA3025869A1 (en) 2017-12-21
KR20190018504A (ko) 2019-02-22
NI201800134A (es) 2019-03-05
CO2018013434A2 (es) 2018-12-28
MX2023012740A (es) 2024-02-23
US11479615B2 (en) 2022-10-25
AR108717A1 (es) 2018-09-19
US11512142B2 (en) 2022-11-29
JOP20180121A1 (ar) 2018-12-12

Similar Documents

Publication Publication Date Title
CO2018013434A2 (es) Anticuerpos antifactor de la coagulación xi
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
EA202091540A1 (ru) Антитела к lilrb2
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
DOP2015000269A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
CR20150578A (es) Heterociclos bicíclicos como inhibidores de fgfr
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201991997A1 (ru) Комбинированная терапия
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.